Background: Oxidative stress is associated with a diverse group of liver disorders across species.
oxidative imbalance contributing to the pathogenesis of these disorders. 1 The liver plays a vital role in regulating the body's endogenous antioxidant status, as it is the primary site for glutathione synthesis, the major intracellular antioxidant. 2 In people with naturally occurring liver disease and in animal models of induced hepatopathies liver glutathione concentration is decreased. [2] [3] [4] [5] [6] Similar to people, both dogs and cats with liver disease have decreased liver glutathione concentration. 7, 8 People with autoimmune liver disease have decreased glutathione concentration in peripheral whole blood, and decreases in plasma and erythrocyte glutathione can be directly correlated to the severity of the liver disease. 3, 9 In addition, plasma vitamin E concentration is negatively correlated with hepatocyte apoptosis in human patients with chronic hepatitis. 9 Urinary isoprostanes variably correlate with oxidative stress in dogs, and urinary isoprostane concentration increases with severity of autoimmune liver disease in human patients. 9, 10 Taken together, these data indicate that increased oxidative stress is associated with progression of liver disease.
What these human and canine studies have not yet investigated is whether markers of oxidative stress in blood or urine reflect liver concentrations. In a recent review, blood reduced glutathione (GSH) and vitamin E concentrations trend with tissue concentrations in experimental animal models used to induce oxidative stress. 11 Glutathione concentration in blood accurately reflects the redox status of several tissues (ie, liver, heart, and skeletal muscle) in rats. 4 Blood glutathione concentration is significantly and directly correlated with liver glutathione concentration in healthy rats, and rats experimentally subjected to an oxidative challenge. To our knowledge, similar studies in patients with naturally occurring liver disease have not been reported in either people or dogs.
The medical management of liver disease often includes antioxidant supplementation, most commonly with glutathione precursors to replenish glutathione concentrations. Measuring liver glutathione concentration requires biopsy specimen collection and is invasive. If peripheral antioxidant concentrations were found to correlate with liver antioxidant concentration, these peripheral markers would provide a clinically useful tool for assessing the progression of liver disease and response to treatment. Liver biopsies were submitted for routine histopathology for clinical case management. All cases were reviewed by a single anatomic pathologist (Marie E. Pinkerton) and classified using WSAVA guidelines. 18 Additional clinical diagnostics were pursued on per case basis at the discretion of the attending clinician to include heavy metal analysis (liver tissue) and bacterial culture (liver or bile), with results recorded when available.
| Sample collection

| Erythrocyte, plasma, and liver glutathione analysis
Blood was added to heparinized tubes and monobromobimane added within 1 minute of venipuncture for evaluation of erythrocyte and plasma GSH. Within 30 minutes of heparinized blood collection, plasma and packed RBCs were separated, harvested, and frozen at −80 C before analysis. Plasma, erythrocyte, and liver GSH were determined within 7 days of blood collection. When possible, all samples were run in duplicate. Glutathione concentrations were determined using high performance liquid chromatography (HPLC). Plasma GSH concentration was measured by a method similar to a plasma cysteine determination used previously. 19 Briefly, 7.5 μL 180 mM monobromobimane and 62.5 μL 1Xphosphate-buttered saline (PBS) was added to 437 μL monobromobimane-treated plasma. Proteins were precipitated by addition of 40 μL 50% sulfosalicylic acid (SSA) in 500 μM dithiothreitol (DTT). After centrifugation, 400 μL was transferred to a fresh amber tube and 4.5 μL 50% SSA in 500 μM DTT, 10.2 μL 1 M N-Ethylmopholine, and 16 μL acetonitrile was added. After incubation at 37 C in the dark, 15 μL trichloroacetic acid was added and the sample was filtered using a 0.2-μm centrifugal filter. The limit of quantitation of plasma GSH was 0.5 μM with an intra-assay CV of 0.37%-8.75%.
Erythrocyte GSH was determined as previously reported with the following exception. 19 Packed erythrocytes (62.5 μL) were added to 62.5 μL 1X PBS for a total volume of 142.5 μL. Liver GSH was quantified using the same method as for erythrocytes with the following alteration. For liver tissue GSH determination, 0.1 g of tissue was combined with 900 μL of ice cold 2.7 mM monobromobimane in 1XPBS and homogenized for 1-2 minutes with 0.5 μm zirconium beads in a Bullet Blender (Next Advance, Averill, New York). The liver sample was centrifuged at 3000 g for 15 minutes at 4 C and the supernatant removed to a fresh amber tube befire assay. 
| Plasma vitamin E analysis
Two milliliters of venous blood were added to an EDTA tube within 1 minute of collection, protected from light with foil, and kept on ice for evaluation of vitamin E. Samples were stored frozen before analysis and assays were completed within 7 days of blood collection through the Wisconsin Veterinary Diagnostic Laboratory (Madison, Wisconsin). Quantification of plasma vitamin E was performed using HPLC, as previously described. 
| Urine 8-isoprostane analysis
| Statistical analysis
Before study commencement, a power calculation was performed based on the previous work in rodents. 4 Based on this calculation, the target enrollment was 34 dogs to provide 90% power to detect a modest correlation of 0.5.
Continuous variables (age, body weight, and F 2 -IsoPs/Cr) were compared between the dogs with liver disease and healthy controls using the Mann-Whitney U-test. Categorical data (breed and sex)
were compared using Fisher's exact test. Circulating markers of oxidative stress (ie, erythrocyte and plasma GSH, plasma vitamin E, and F 2 -IsoPs/Cr) were compared to liver GSH using a Spearman's rank correlation (rho). Statistical calculations were performed with a commercial software package (GraphPad Prism 7.04), with P < .05 considered significant.
3 | RESULTS
| Study population
A total of 49 dogs were enrolled into the study, 34 dogs with liver disease and 15 healthy control dogs for were not fed a prescription liver diet, and in 17 dogs, diet was not specified.
| Liver histopathology
Primary or secondary liver disease was confirmed in all dogs on the basis of liver histopathology and classified as: (1) 
| Biomarkers of oxidative stress
Median GSH concentrations in plasma, erythrocyte, and liver were 0.18 mg/dL (5.76 μM; range 0.14-0.56 mg/dL, n = 31), 56.7 mg/dL Liver GSH did not differ significantly between dogs receiving antioxidant supplementation and dogs not receiving supplementation (P = .50), nor did plasma or erythrocyte GSH differ between these groups (P = .94 and P = .41 respectively). Likewise, plasma vitamin E and F 2 -IsoPs/Cr did not differ between supplemented and nonsupplemented groups (P = .45 and P = .15 respectively). No correlations were found between liver GSH and any of the peripheral markers studied when groups were divided into those receiving antioxidant Liver GSH concentration did not correlate with other systemic markers of oxidative stress in this group of dogs undergoing a clinically indicated liver biopsy. This is in contrast to what we hypothesized based on experimentally induced acute oxidative injury models in rodents. 4 In rats, oxidized glutathione (GSSG) concentrations correlate between blood and liver within <12 hours of exhaustive exercise or allupurinol administration. 4 In rats treated with L-buthionine-[S,R]-sulfoximine (BSO) to deplete body stores of glutathione, both GSH and GSSG in the plasma and in the liver decrease with exhaustive exercise, though correlation between plasma and liver has not been directly assessed. 22 Other than species or analytical method differences, possible reasons for the observed study differences from these studies and this clinical study could be in the oxidative markers stud- 23 In exercised rats with normal glutathione stores, plasma GSH does not change significantly with exhaustive exercise, while liver GSH decreases. 22 The overall findings of the current study do not support the use of systemic markers of oxidative stress in blood or urine as an indicator of liver redox status in dogs, despite these compartments being more readily assessable for routine noninvasive sampling.
The etiologies of liver disease in people are often different from those that affect dogs, despite excessive lipid peroxidation being a common feature of liver injury across species. 23, 24 In people, increased markers of lipid peroxidation, both urine 8-isoprostanes and serum protein carbonyls, are associated with noncirrhotic and cirrhotic autoimmune cholestatic liver disease and cirrhotic autoimmune hepatitis. 9 Other studies in dogs have demonstrated altered endogenous antioxidants in dogs with liver disease, with decreased GSH reported in both the liver and erythrocytes. 5, 7, 8 Taken together, multiple markers of oxidative stress are altered in dogs undergoing a clinically indicated liver biopsy. Extrapolating from what is known about mechanisms of liver injury and studies in animals and humans with liver injury, systemic oxidative stress likely contributes to disease progression. [24] [25] [26] [27] In addition, this study further suggests that exogenous antioxidants, limited to supplementation with a glutathione source, do not resolve underlying systemic lipid peroxidation.
This study had several limitations. GSH was evaluated, but not oxidized or total glutathione, and correlations might have been found between these alternate forms of glutathione. Indeed, in rats subjected to oxidative stress, GSSG in blood and liver tissue, rather than GSH, correlates significantly. 4 However, GSH represents the most biologically active form (capable of halting redox reactions), and thus seemingly the most clinically relevant; it has also previously been found to be decreased within the liver in dogs with spontaneous hepatopathies. 7 This study also evaluated a heterogeneous group of dogs with primary or secondary liver disease, and it is possible that correlations might exist only in certain subsets of dogs, such as those with inflammatory disease or minimal fibrosis. The number of dogs in this study did not allow further analysis by category of disease. In addition, the overall number of dogs analyzed in this study was relatively small, which might have limited our power to observe statistical correlations. In addition, this study did not control antioxidant supplementation provided to dogs. As so few direct treatments for liver disease exist, antioxidant supplementation regardless of etiology is a mainstay of its treatment. Thus, most dogs are receiving antioxidant supplementation at the time of liver biopsy. Such supplementation could have affected results (if, eg, supplementation increased glutathione concentration in the blood but not the liver). Lastly, the dogs in the control and study populations differed significantly in both weight and breed. While this difference could have contributed to the significant difference found in urine isoprostane concentrations between the 2 groups, the control group was heavier, and oxidative stress is greater in larger animals. 28 In conclusion, this study did not demonstrate significant correlations between liver GSH concentration and several peripheral markers of oxidative stress. This information is clinically relevant, demonstrating that measuring only blood or urine markers in dogs with liver disease is inadequate for assessing the degree of oxidative damage at the primary site of disease, or the therapeutic response. In addition, this study demonstrated significantly higher F 2 -IsoPs/Cr concentration in dogs undergoing a clinically indicated liver biopsy compared to healthy controls. This increased concentration suggests that in this study population oxidative stress persisted despite prevalent antioxidant supplementation.
